In a PDX model of pediatric neuroblastoma harboring mutations of anaplastic lymphoma kinase (ALK), CDK-i synergized with the ALK inhibitor, Ceritinib, inducing cell-cycle arrest and cell death (63). This evidence concerns the gene ALK and neuroblastoma.